Shire to acquire UCB's Equasym

Shire (LSE:SHP; NASDAQ:SHPGY) will acquire exclusive, worldwide rights from UCB (Euronext:UCB) to ADHD drug Equasym methylphenidate IR and XL for EUR 55 million ($70.1 million) up front in cash. The deal excludes the U.S., Canada and Barbados. Outside of those territories, the XL and IR versions of the drug are marketed in 10 and four countries, respectively, and had combined 2008 net sales of EUR 16.9 million ($21.5 million). UCB is eligible for undisclosed sales milestones in the deal, which is expected to close next quarter. ...